Hitchhiking drug targets Hard-to-Treat cancers in early trial
NCT ID NCT05352750
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called SON-1010 in 42 adults with advanced solid tumors that have spread or cannot be removed. The drug is designed to hitch a ride on a blood protein called albumin to deliver an immune-boosting signal (IL-12) directly to the tumor area. The main goals are to check safety, find the best dose, and see how the body processes the drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SON-1010 (IL12-FHAB), a biologic drug that carries interleukin-12 to tumors by binding to albumin in the blood
What this could lead to
If it works, this could point toward a new treatment option for advanced solid tumors that are hard to treat.
What could go wrong
This is a very early Phase 1 trial with only 42 people, so it is mainly checking safety and dosing. The drug may not shrink tumors or could cause side effects like immune overactivation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sarcoma Oncology Center
Santa Monica, California, 90403, United States